Encapsulated 3D-Bioprinted Structure Seeded with Urothelial Cells: A New Method for Tissue-Engineered Urinary Tract Patches
Urinary tract strictures—narrowed sections caused by trauma, infection, or long-term catheter use—force millions of people into surgery to rebuild damaged tissue. But relying on autologous (patient’s own) tissue like buccal mucosa or prepuce comes with tradeoffs: harvesting these tissues is painful, risks complications like infection or bleeding, and often leaves too little tissue for repeat procedures. For decades, researchers have searched for a better way to create urinary tract replacements—and a 2020 study from Chinese PLA General Hospital centers offers a promising answer: a 3D-bioprinted patch made from stem cells and the cells that line the urinary tract.
The Problem with Traditional Tissue Engineering
Traditional tissue engineering uses scaffolds—porous materials like collagen or synthetic polymers—where cells are “seeded” on top and left to grow inward. This process takes weeks, and cells often die, spread unevenly, or fail to replicate the urinary tract’s layered structure (smooth muscle beneath a protective urothelial lining). Natural scaffolds (like bladder acellular matrix) risk disease transmission; synthetic ones (like PLGA) lack the chemical signals cells need to attach and grow. Neither solves the core issue: getting cells to stay in the right place and function like native tissue.
How the 3D-Bioprinted Patch Works
The team’s approach combines 3D bioprinting—additive manufacturing for living tissue—with stem cell biology to build a patch that mimics the urinary tract’s structure and function. Here’s the breakdown:
1. Stem Cell Microtissues
The researchers used human adipose-derived stem cells (hADSCs)—easy to harvest from fat and capable of turning into smooth muscle cells (critical for pushing urine through the tract). They grew hADSCs in a “smooth muscle inductive medium” to create induced microtissues (ID-MTs)—small cell clusters that act like mature smooth muscle. Non-induced microtissues (NI-MTs) served as a control.
2. 3D Bioprinting
Using a micro-extrusion 3D bioprinter, the team embedded hADSCs, NI-MTs, or ID-MTs into a gelatin-alginate hydrogel—a soft, biocompatible material that mimics human tissue. The printer built a 2cm × 1cm × 1cm structure (scalable for larger defects) with precise cell placement—something traditional scaffolds can’t do.
3. Encapsulation
The printed structures were implanted under the skin of nude mice for 7 days. The mouse’s body formed a thin, protective capsule around the patch—this “pre-conditioning” helps cells attach better later and reduces inflammation.
4. Urothelial Lining
After retrieving the encapsulated structures, the team seeded human urothelial cells (UCs)—grown from ureteral tissue—on top. Urothelial cells form the urinary tract’s impermeable barrier, preventing urine from leaking into deeper tissues. The cells were left to grow for a week to form a tight monolayer.
Key Results: A Patch That Acts Like Native Tissue
The study, published in Chinese Medical Journal, yielded three breakthrough findings:
1. Better Vascularization & Anti-Inflammation
Microtissues (both ID-MTs and NI-MTs) produced 2x more VEGFA (a protein that grows blood vessels) and 2.5x more TSG-6 (an anti-inflammatory protein) than single hADSCs. More VEGFA means the patch gets the blood flow it needs to survive; more TSG-6 means less risk of rejection or inflammation—two major reasons grafts fail.
2. Smooth Muscle Mimicry
ID-MTs (induced to be smooth muscle) formed 2.4x more smooth muscle fibers (stained red with Masson’s trichrome) and half as much collagen (stained blue) as NI-MTs. This is exactly what the native urinary tract has: a thick smooth muscle layer to propel urine. The ID-MTs also had high levels of a-SMA and smoothelin—proteins that mark mature smooth muscle—proving they kept their function after implantation.
3. Impermeable Urothelial Barrier
Urothelial cells seeded on the encapsulated structures formed a tight monolayer (single cell layer) and expressed AE1/AE3—a marker for functional urothelial cells. This is critical: the natural urinary tract’s barrier prevents urine from damaging surrounding tissue, and the patch replicated this perfectly.
Why This Matters for Patients
This method solves three major flaws in traditional tissue engineering:
- Speed: 3D bioprinting builds the structure with cells inside—no waiting for cells to grow in. The entire process (printing + encapsulation + seeding) takes ~2 weeks, compared to 2–3 weeks for traditional methods.
- Structure: The patch mimics the urinary tract’s layered design—smooth muscle under urothelial cells. This is impossible with most scaffolds, where cells spread randomly.
- Survival: Microtissues’ high VEGFA and TSG-6 mean better blood flow and less inflammation—two of the biggest barriers to successful grafts.
Next Steps
The team plans to test the patch on beagles with urinary tract defects—a larger animal model that better mimics human anatomy. If the patch works in beagles, the next step is clinical trials in humans. The ultimate goal is to create “off-the-shelf” patches—ready to use when a patient needs them—eliminating the wait for cell growth.
Conclusion
This study shows how 3D bioprinting and tissue engineering can merge to create a urinary tract patch that’s closer to native tissue than ever before. By using stem cell microtissues for smooth muscle and urothelial cells for the barrier, the researchers have built a patch that’s functional, fast to make, and more likely to survive in the body. For patients with urinary tract strictures, this could mean fewer complications, faster recovery, and a second chance at a healthy urinary tract.
Jin YP, Shi C, Wu YY, Sun JL, Gao JP, Yang Y. Encapsulated three-dimensional bioprinted structure seeded with urothelial cells: a new construction technique for tissue-engineered urinary tract patch. Chinese Medical Journal 2020;133(4):424–434. doi:10.1097/CM9.0000000000000654
Was this helpful?
0 / 0